Sonali Bose, MD
Pulmonary Disease · New York, NYNPI 1912024464
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,568 of the $16,079 with a category attached, or 90.6%. Reporting peaked in 2024 at $12,179 and has fallen 68.3% since, to $3,862 in 2025.
Across 22 payments — averaging $730.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$10K
- Regeneron Healthcare Solutions, Inc.$6K
Across 1 payment — averaging $86,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- 4dmedical USA Inc$86K
What the payments were for
- Consulting fees$14,56891%
- Travel & lodging$7655%
- Food & beverage$7455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $9,637 |
| Regeneron Healthcare Solutions, Inc. | 17 | $6,442 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$6,128
How this compares
$16,079 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $148,771 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $21,285 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $9,728 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,099 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,900 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 185 | $5,951 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,810 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,554 |
| Nystatin | 17 | $543 |
| Montelukast Sodium | 52 | $494 |
| Azelastine Hcl | 17 | $432 |
| Fluticasone Propionate | 34 | $412 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.